307 related articles for article (PubMed ID: 21376994)
1. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
2. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Isharwal S; Makarov DV; Sokoll LJ; Landis P; Marlow C; Epstein JI; Partin AW; Carter HB; Veltri RW
Urology; 2011 Mar; 77(3):763.e1-6. PubMed ID: 21216447
[TBL] [Abstract][Full Text] [Related]
3. Editorial comment.
Carroll PR; Whitson JM
Urology; 2011 Apr; 77(4):984-5. PubMed ID: 21477729
[No Abstract] [Full Text] [Related]
4. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.
Tosoian JJ; Trock BJ; Landis P; Feng Z; Epstein JI; Partin AW; Walsh PC; Carter HB
J Clin Oncol; 2011 Jun; 29(16):2185-90. PubMed ID: 21464416
[TBL] [Abstract][Full Text] [Related]
5. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
6. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
[TBL] [Abstract][Full Text] [Related]
7. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
8. Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Gallina A
Eur Urol; 2010 Apr; 57(4):639. PubMed ID: 19299073
[No Abstract] [Full Text] [Related]
9. Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer.
Yossepowitch O
Eur Urol; 2010 Apr; 57(4):639-40. PubMed ID: 19299071
[No Abstract] [Full Text] [Related]
10. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
11. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml.
Lodeta B; Benko G; Car S; Filipan Z; Stajcar D; Dujmović T
Acta Clin Croat; 2009 Jun; 48(2):153-5. PubMed ID: 19928413
[TBL] [Abstract][Full Text] [Related]
13. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
Philip J
Eur Urol; 2008 May; 53(5):981-2. PubMed ID: 17997013
[No Abstract] [Full Text] [Related]
14. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: reassessing the diagnostic yield of saturation biopsy of the prostate.
Patel A
Eur Urol; 2008 May; 53(5):982-3. PubMed ID: 17997023
[No Abstract] [Full Text] [Related]
16. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.
Lein M; Semjonow A; Graefen M; Kwiatkowski M; Abramjuk C; Stephan C; Haese A; Chun F; Schnorr D; Loening SA; Jung K
J Urol; 2005 Dec; 174(6):2150-3. PubMed ID: 16280753
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of expectant management with inner-city men with newly diagnosed localized prostate cancer.
Anai S; Nakamura K; Chang MN; Pendleton J; Yacoub S; Rosser CJ
J Health Care Poor Underserved; 2008 Feb; 19(1):164-70. PubMed ID: 18263992
[TBL] [Abstract][Full Text] [Related]
18. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Albertson PC
Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
[No Abstract] [Full Text] [Related]
20. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Aus G
Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
[No Abstract] [Full Text] [Related]
[Next] [New Search]
